Since its inception in early 2014, the SAG initiative has exercised considerable impact on the clinical research landscape by inciting important dialogue between site professionals and industry leaders related to current and evolving practices.
The Society for Clinical Research Sites, the global trade organization dedicated to representing the interests of clinical research sites, today announced new developments to its landmark Site Advocacy Group initiative. The Site Advocacy Group (SAG) initiative enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools, and technologies.
Since its inception in early 2014, the SAG initiative has exercised considerable impact on the clinical research landscape by inciting important dialogue between site professionals and industry leaders related to current and evolving practices.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.